How big is the Gene Vector Market?

The Gene Vector Market size is expected to reach USD 1.68 billion in 2024 and grow at a CAGR of 12.45% to reach USD 3.02 billion by 2029. Read More

What is the current Gene Vector Market size?

In 2024, the Gene Vector Market size is expected to reach USD 1.68 billion. Read More

Who are the key players in Gene Vector Market?

Charles River Laboratories International Inc, Fujifilm Diosynth Biotechnologies, Kaneka Eurogentec SA, Merck KGaA and uniQure biopharma BV are the major companies operating in the Gene Vector Market. Read More

Which is the fastest growing region in Gene Vector Market?

Asia Pacific is estimated to grow at the highest CAGR over the forecast period (2024-2029). Read More

Which region has the biggest share in Gene Vector Market?

In 2024, the North America accounts for the largest market share in Gene Vector Market. Read More

What years does this Gene Vector Market cover, and what was the market size in 2023?

In 2023, the Gene Vector Market size was estimated at USD 1.47 billion. The report covers the Gene Vector Market historical market size for years: 2019, 2020, 2021, 2022 and 2023. The report also forecasts the Gene Vector Market size for years: 2024, 2025, 2026, 2027, 2028 and 2029. Read More

Gene Vector Market Share

Statistics for the 2023 & 2024 Gene Vector market share, created by Mordor Intelligence™ Industry Reports. Gene Vector share report includes a market forecast to 2029 and historical overview. Get a sample of this industry share analysis as a free report PDF download.

Market Share of Gene Vector Industry

The gene vector market is moderately fragmented in nature due to the presence of several companies operating globally as well as regionally. The competitive landscape includes an analysis of a few international as well as local companies that hold significant market share and are well known, including Cell Therapy Catapult Ltd, Charles River Laboratories International Inc., Fujifilm Diosynth Biotechnologies, Genezen Laboratories Inc., Kaneka Eurogentec SA, Lonza Group Ltd, Merck KGaA, Oxford Biomedica PLC, Spark Therapeutics Inc., and uniQure biopharma BV.